Skip to main content

Correction to: Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals

The Original Article was published on 31 May 2018

Correction to: BMC Health Serv Res (2018) 18:393

https://doi.org/10.1186/s12913-018-3162-2

In the original publication of this article [1], the Acknowledgements section lacks of important funding information “This project was funded by the NIHR Oxford Biomedical Research Centre BRC”. The authors apologize for any inconvenience that it may have caused.

Reference

  1. Morrell, et al. Will the reformed Cancer drugs fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals. BMC Health Serv Res. 2018;18(393). https://doi.org/10.1186/s12913-018-3162-2.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Liz Morrell.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Morrell, L., Wordsworth, S., Schuh, A. et al. Correction to: Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals. BMC Health Serv Res 19, 198 (2019). https://doi.org/10.1186/s12913-019-4039-8

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s12913-019-4039-8